RxDoctor Payments Data

Elliott Salamon, DO

Neurology · New Hyde Park, NYNPI 1609063486

Payments from drug & device makers

$48,414in general payments, 2019–2025

Across 975 payments — averaging $49.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$31K
  • AbbVie$5K
  • Boston Scientific$3K
  • SK Life Science, Inc.$1K
  • Amgen$806
  • Pfizer$687
  • plus $7K from 47 others

What the payments were for

  • Consulting fees$7502%
  • Speaking & faculty fees$27,78157%
  • Travel & lodging$1,0932%
  • Food & beverage$18,77639%
  • Education$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,414 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$1,152,349
Medicare patients
1,186
Services billed
6,916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant82$127,172
Nurtec OdtRimegepant Sulfate68$113,533
QuliptaAtogepant82$84,922
EliquisApixaban20$18,781
Rivastigmine63$15,577
Memantine Hcl298$7,355
Donepezil Hcl746$6,799
Lacosamide86$6,457
Levetiracetam225$5,457
Pregabalin194$4,097
Enoxaparin Sodium12$3,803
Carbidopa-LevodopaCarbidopa/Levodopa210$3,524
Quetiapine Fumarate183$2,687
Rasagiline Mesylate27$2,251
Duloxetine Hcl159$2,198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$5,095$212,094164 claims
PfizerNurtec Odt, Eliquis$687$132,31388 claims
Upsher-smith Laboratories LLCTopiramate$119$8834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,623 neurology providers in New York.

Other neurology in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →